Considering that GLP-1R agonists are FDA approved drugs to treat T2DM and also ameliorate NASH, in the present study we evaluated the efficacy of a GLP-1R agonist in two mouse models: one model with NASH-like features (methionine and choline-deficient (MCD) diet), and a second high-fat model of metabolic syndrome and hepatic dysfunction. Here, GLP1R is linked to metabolic syndrome.